AMCAD BIOMED CORPORATION Financials AmCad BioMed Corporation
Equities
4188
TW0004188008
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.65 TWD | -0.74% |
|
-1.84% | -0.19% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,450 | 1,282 | 1,027 | 1,030 | 848.9 | 1,422 |
| Enterprise Value (EV) 1 | 952.7 | 840.2 | 636.3 | 673.5 | 528.4 | 1,149 |
| P/E ratio | -32.4 x | -34 x | -29 x | -40.3 x | -15.9 x | -31.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 20 x | 15.3 x | 16.1 x | 12 x | 13.8 x | 21.8 x |
| EV / Revenue | 13.2 x | 9.99 x | 9.95 x | 7.85 x | 8.57 x | 17.6 x |
| EV / EBITDA | -13.9 x | -18.8 x | -15.1 x | -28.7 x | -10.3 x | -27.9 x |
| EV / FCF | -9.6 x | -49.2 x | -20.9 x | -20.4 x | -26.2 x | -39.6 x |
| FCF Yield | -10.4% | -2.03% | -4.79% | -4.91% | -3.82% | -2.52% |
| Price to Book | 2.53 x | 2.41 x | 2.06 x | 2.13 x | 2 x | 3.74 x |
| Nbr of stocks (in thousands) | 52,912 | 52,990 | 53,221 | 53,221 | 53,221 | 53,256 |
| Reference price 2 | 27.40 | 24.20 | 19.30 | 19.35 | 15.95 | 26.70 |
| Announcement Date | 26/02/19 | 23/03/20 | 09/03/21 | 02/03/22 | 08/03/23 | 29/02/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 72.32 | 84.09 | 63.94 | 85.79 | 61.63 | 65.26 |
| EBITDA 1 | -68.57 | -44.6 | -42.01 | -23.46 | -51.48 | -41.26 |
| EBIT 1 | -80.09 | -56.29 | -56.26 | -36.77 | -64.3 | -53.98 |
| Operating Margin | -110.74% | -66.94% | -87.99% | -42.86% | -104.33% | -82.73% |
| Earnings before Tax (EBT) 1 | -42.28 | -47.5 | -43.02 | -26.89 | -54.34 | -43.15 |
| Net income 1 | -44.68 | -37.74 | -35.44 | -25.54 | -53.49 | -45.31 |
| Net margin | -61.78% | -44.88% | -55.43% | -29.77% | -86.79% | -69.44% |
| EPS 2 | -0.8451 | -0.7124 | -0.6666 | -0.4800 | -1.005 | -0.8513 |
| Free Cash Flow 1 | -99.22 | -17.09 | -30.47 | -33.04 | -20.2 | -29.01 |
| FCF margin | -137.19% | -20.32% | -47.66% | -38.52% | -32.78% | -44.46% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 26/02/19 | 23/03/20 | 09/03/21 | 02/03/22 | 08/03/23 | 29/02/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 497 | 442 | 391 | 356 | 321 | 273 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -99.2 | -17.1 | -30.5 | -33 | -20.2 | -29 |
| ROE (net income / shareholders' equity) | -6.47% | -7.16% | -6.98% | -4.58% | -9.89% | -8.65% |
| ROA (Net income/ Total Assets) | -6.77% | -4.65% | -5.06% | -3.61% | -6.87% | -6.33% |
| Assets 1 | 659.7 | 811.5 | 701 | 707.1 | 778.4 | 716.2 |
| Book Value Per Share 2 | 10.80 | 10.10 | 9.350 | 9.070 | 7.980 | 7.150 |
| Cash Flow per Share 2 | 2.550 | 2.050 | 1.120 | 1.100 | 0.8800 | 0.5600 |
| Capex 1 | 66.1 | 4.36 | 0.32 | 2.34 | 0.61 | 0.29 |
| Capex / Sales | 91.38% | 5.18% | 0.5% | 2.72% | 1% | 0.45% |
| Announcement Date | 26/02/19 | 23/03/20 | 09/03/21 | 02/03/22 | 08/03/23 | 29/02/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -0.19% | 44.33M | |
| -15.34% | 18.88B | |
| -41.10% | 2.84B | |
| +24.02% | 1.85B | |
| +8.62% | 1.66B | |
| +26.63% | 1.26B | |
| -7.74% | 989M | |
| -18.61% | 896M | |
| -1.03% | 757M | |
| -23.76% | 637M |
- Stock Market
- Equities
- 4188 Stock
- Financials AmCad BioMed Corporation